DE602004011061D1 - Erhöhte t-zell tumor-eindringung durch light- mutanten - Google Patents

Erhöhte t-zell tumor-eindringung durch light- mutanten

Info

Publication number
DE602004011061D1
DE602004011061D1 DE602004011061T DE602004011061T DE602004011061D1 DE 602004011061 D1 DE602004011061 D1 DE 602004011061D1 DE 602004011061 T DE602004011061 T DE 602004011061T DE 602004011061 T DE602004011061 T DE 602004011061T DE 602004011061 D1 DE602004011061 D1 DE 602004011061D1
Authority
DE
Germany
Prior art keywords
increased
cell tumor
light
improvement
mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004011061T
Other languages
English (en)
Other versions
DE602004011061T2 (de
Inventor
Yang-Xin Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of DE602004011061D1 publication Critical patent/DE602004011061D1/de
Application granted granted Critical
Publication of DE602004011061T2 publication Critical patent/DE602004011061T2/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004011061T 2003-06-11 2004-06-10 Erhöhte t-zell tumor-eindringung durch light- mutanten Active DE602004011061T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47773303P 2003-06-11 2003-06-11
US477733P 2003-06-11
US47812603P 2003-06-12 2003-06-12
US478126P 2003-06-12
PCT/US2004/018631 WO2005002628A1 (en) 2003-06-11 2004-06-10 Increased t-cell tumor infiltration by mutant light

Publications (2)

Publication Number Publication Date
DE602004011061D1 true DE602004011061D1 (de) 2008-02-14
DE602004011061T2 DE602004011061T2 (de) 2008-11-06

Family

ID=33567565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004011061T Active DE602004011061T2 (de) 2003-06-11 2004-06-10 Erhöhte t-zell tumor-eindringung durch light- mutanten

Country Status (9)

Country Link
US (1) US7807784B2 (de)
EP (1) EP1641491B1 (de)
JP (1) JP5049011B2 (de)
AT (1) ATE382372T1 (de)
AU (1) AU2004253465A1 (de)
CA (1) CA2529058A1 (de)
DE (1) DE602004011061T2 (de)
ES (1) ES2297479T3 (de)
WO (1) WO2005002628A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
WO2007003216A1 (en) * 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
US20090093429A1 (en) * 2007-02-08 2009-04-09 Yang-Xin Fu Combination therapy for treating cancer
WO2008144029A1 (en) 2007-05-14 2008-11-27 The University Of Chicago Antibody-light fusion products for cancer therapeutics
CN104151434B (zh) * 2008-05-07 2018-12-04 苏州丁孚靶点生物技术有限公司 预防和治疗原发和转移性癌症的light-抗肿瘤抗原抗体
US8263823B2 (en) * 2008-10-20 2012-09-11 Adimmu Institute Inc. Immunocompetent xenograft model
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
EP2790730B1 (de) 2011-12-15 2019-01-23 The University of Chicago Verfahren und zusammensetzungen zur krebstherapie mit mutanten leichtmolekülen mit erhöhter rezeptoraffinität
CN116083435A (zh) * 2022-11-04 2023-05-09 吉林大学 以人源light截短型突变蛋白为基础的抗肿瘤的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
JP2001509135A (ja) 1996-10-11 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2001079496A2 (en) 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU2002224388A1 (en) 2000-10-18 2002-04-29 Smith Kline Beecham Corporation Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules
WO2002034780A2 (en) 2000-10-26 2002-05-02 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Hetero-oligomeric compounds derived from the tnf cytokine superfamily and their use
AU2002363354A1 (en) * 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members

Also Published As

Publication number Publication date
EP1641491B1 (de) 2008-01-02
CA2529058A1 (en) 2005-01-13
US20050025754A1 (en) 2005-02-03
EP1641491A1 (de) 2006-04-05
JP2007516694A (ja) 2007-06-28
WO2005002628A1 (en) 2005-01-13
ES2297479T3 (es) 2008-05-01
AU2004253465A1 (en) 2005-01-13
US7807784B2 (en) 2010-10-05
DE602004011061T2 (de) 2008-11-06
ATE382372T1 (de) 2008-01-15
JP5049011B2 (ja) 2012-10-17

Similar Documents

Publication Publication Date Title
MY163032A (en) Human anti-il-23 antibodies, compositions, methods and uses
DE602004011061D1 (de) Erhöhte t-zell tumor-eindringung durch light- mutanten
MEP32608A (en) Antibodies to opgl
WO2004007679A3 (en) Dendritic cell pontentiation
GB0503936D0 (en) Method
NZ596494A (en) Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
WO2009014708A3 (en) Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
TW200712688A (en) Light diffusing films, methods of making the same, and articles using the same
MX2009008620A (es) Un metodo para mejorar la respuesta de celulas t.
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
EP1483281A4 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
EP2258712A3 (de) Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
TW200722439A (en) Oval-spherical organic polymer particle and method of production
AU2003244100A1 (en) Acrylic resin composition, organosiloxane resin composition and laminates made by using them
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
WO2005044792A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
TW200700726A (en) Autoantibody detection for cancer diagnostics
GB2458416A (en) Seat track assembly
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
IL177179A0 (en) Methods of refolding mammaliam glycosyltransferases
MXPA03002863A (es) Valoracion de cancer colorrectal.
AU2003254196A8 (en) Methods for producing biological substances in pigment-deficient mutants of bacillus cells
WO2003078595A3 (en) Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response

Legal Events

Date Code Title Description
8364 No opposition during term of opposition